Data / Drug companies / Antimetabolite Immunosuppressant
Antimetabolite Immunosuppressant drugs: 4 drugs from 47 companies in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Antimetabolite Immunosuppressant is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 100 products in this class from 47 companies, covering 4 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on October 15, 2026.
The request: Get every company that lists a Antimetabolite Immunosuppressant drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 47Companies
- 100Products
- 4Drugs by generic name
Drugs in the Antimetabolite Immunosuppressant class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Mycophenolate mofetil | 61 | 37 |
| Mycophenolic acid | 35 | 16 |
| Mycophenolate mofetil hydrochloride | 2 | 2 |
| Mycophenilic acid | 2 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Ascend Laboratories, LLC | 7 | tablet, delayed release; capsule | Generic drugs (ANDA) | April 21, 2026 |
| Aurobindo Pharma Limited | 5 | tablet, delayed release; powder, for suspension | Generic drugs (ANDA) | September 26, 2024 |
| Major Pharmaceuticals | 5 | tablet, delayed release; capsule | Generic drugs (ANDA) | December 11, 2025 |
| Remedyrepack Inc. | 5 | capsule; tablet, film coated | Generic drugs (ANDA) | July 15, 2025 |
| Accord Healthcare Inc. | 4 | tablet, delayed release; capsule | Generic drugs (ANDA) | September 11, 2017 |
| Advagen Pharma Ltd | 4 | tablet, delayed release; capsule | Generic drugs (ANDA) | November 10, 2023 |
| Biocon Pharma Inc. | 4 | tablet, delayed release | Generic drugs (ANDA) | September 30, 2024 |
| Concord Biotech Limited | 4 | tablet, delayed release; capsule | Generic drugs (ANDA) | December 21, 2020 |
| Genentech, Inc. | 4 | injection, powder, lyophilized, for solution; capsule | New drug applications (NDA) | October 1, 1998 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 3 | capsule; powder, for suspension | Generic drugs (ANDA) | September 5, 2023 |
| Strides Pharma Science Limited | 3 | powder, for suspension; capsule | Generic drugs (ANDA) | September 1, 2026 |
| A-S Medication Solutions | 2 | tablet, delayed release; tablet, film coated | Generic drugs (ANDA) | September 24, 2021 |
| American Health Packaging | 2 | capsule; tablet, film coated | Generic drugs (ANDA) | April 2, 2025 |
| American Health Packaging | 2 | tablet, delayed release | Generic drugs (ANDA) | April 2, 2015 |
| Apotex Corp. | 2 | tablet, delayed release | Generic drugs (ANDA) | August 19, 2014 |
| Archis Pharma LLC | 2 | tablet, delayed release | Generic drugs (ANDA) | February 21, 2022 |
| AvKARE | 2 | tablet, film coated; capsule | Generic drugs (ANDA) | April 25, 2025 |
| AvPAK | 2 | capsule; tablet, film coated | Generic drugs (ANDA) | May 15, 2023 |
| Camber Pharmaceuticals, Inc. | 2 | tablet, film coated; capsule | Generic drugs (ANDA) | October 22, 2024 |
| Cardinal Health 107, LLC | 2 | capsule; tablet, film coated | Generic drugs (ANDA) | September 14, 2026 |
| Golden State Medical Supply, Inc. | 2 | tablet, delayed release | Generic drugs (ANDA) | August 19, 2014 |
| Novartis Pharmaceuticals Corporation | 2 | tablet, delayed release | New drug applications (NDA) | February 27, 2004 |
| Novugen Pharma (USA) LLC | 2 | tablet, delayed release | Generic drugs (ANDA) | September 1, 2024 |
| Sandoz Inc | 2 | tablet, film coated; capsule | Generic drugs (ANDA) | October 15, 2008 |
| Slate Run Pharmaceuticals, LLC | 2 | tablet, delayed release | Generic drugs (ANDA) | May 19, 2021 |
| Stellon Biotech Inc. | 2 | tablet, delayed release | Generic drugs (ANDA) | September 11, 2026 |
| Strides Pharma Inc. | 2 | capsule; tablet, film coated | Generic drugs (ANDA) | February 28, 2025 |
| Amneal Pharmaceuticals NY LLC | 1 | powder, for suspension | Generic drugs (ANDA) | March 21, 2024 |
| Amneal Pharmaceuticals NY LLC | 1 | powder, for suspension | Generic drugs (ANDA) | November 5, 2021 |
| Armas Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 6, 2023 |
| Azurity Pharmaceuticals, Inc. | 1 | suspension | New drug applications (NDA) | June 10, 2024 |
| Bpi Labs LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 8, 2023 |
| Bryant Ranch Prepack | 1 | tablet | Generic drugs (ANDA) | May 4, 2009 |
| Hikma Pharmaceuticals USA Inc. | 1 | tablet | Generic drugs (ANDA) | July 29, 2008 |
| Lannett Company, Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | July 29, 2021 |
| Meitheal Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 15, 2021 |
| Mylan Institutional LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 26, 2021 |
| NorthStar RxLLC | 1 | powder, for suspension | Generic drugs (ANDA) | March 1, 2026 |
| NuCare Pharmaceuticals,Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | November 6, 2010 |
| Onesource Specialty Pharma Limited | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 30, 2023 |
| Par Health USA, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 28, 2016 |
| Proficient Rx LP | 1 | tablet, film coated | Generic drugs (ANDA) | October 15, 2022 |
| Quagen Pharmaceuticals LLC | 1 | powder, for suspension | Generic drugs (ANDA) | August 6, 2026 |
| Rising Pharma Holdings, Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | October 15, 2026 |
| Teva Pharmaceuticals USA, Inc. | 1 | capsule | Generic drugs (ANDA) | May 6, 2009 |
| VistaPharm, LLC | 1 | powder, for suspension | Generic drugs (ANDA) | February 15, 2019 |
| Wuxi Fortune Pharmaceutical Co.,Ltd. | 1 | capsule | Generic drugs (ANDA) | November 10, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, delayed release | 37 | 37% |
| Capsule | 20 | 20% |
| Tablet, film coated | 18 | 18% |
| Powder, for suspension | 12 | 12% |
| Injection, powder, lyophilized, for solution | 7 | 7% |
| Tablet | 5 | 5% |
| Suspension | 1 | 1% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.